Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy-Reference-Cited by-同舟云学术

Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Published:2021-08-31 Issue:1 Volume:8 Page:100-103
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Magavern Emma F¹²^ORCID,Kaski Juan Carlos³,Turner Richard M⁴⁵,Drexel Heinz⁶⁷⁸,Janmohamed Azara⁹,Scourfield Andrew¹⁰,Burrage Daniel¹¹,Floyd Christopher N¹²¹³,Adeyeye Elizabeth²,Tamargo Juan¹⁴,Lewis Basil S¹⁵,Kjeldsen Keld Per¹⁶¹⁷,Niessner Alexander¹⁸,Wassmann Sven¹⁹²⁰,Sulzgruber Patrick²¹,Borry Pascal²²²³,Agewall Stefan²⁴,Semb Anne Grete²⁵,Savarese Gianluigi²⁶²⁷,Pirmohamed Munir⁴⁵²⁸,Caulfield Mark J¹

Affiliation:

1. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

2. Department of Clinical Pharmacology, Cardiovascular Medicine, Barts Health NHS Trust, London, UK

3. Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK

4. The Wolfson Centre for Personalised Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, UK

5. Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

6. Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Feldkirch,Austria

7. Private University of the Principality of Liechtenstein, Triesen, Liechtenstein

8. Drexel University College of Medicine, Philadelphia, PA, USA

9. Department of Clinical Pharmacology, St George's University of London, London, UK

10. Department of Clinical Pharmacology, University College London Hospital Foundation Trust, London, UK

11. Whittington Health NHS Trust, London, UK

12. King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK

13. Department of Clinical Pharmacology, Guy's and St Thomas’ NHS Foundation Trust, London, UK

14. Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain

15. Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion—Israel Institute of Technology, Haifa, Israel

16. Department of Cardiology, Copenhagen University Hospital (Amager-Hvidovre), Copenhagen, Denmark

17. Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark

18. Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

19. Cardiology Pasing, Munich,Germany

20. University of the Saarland, Homburg/Saar, Germany

21. Division of Cardiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria

22. Center for Biomedical Ethics and Law, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium

23. Leuven Institute for Human Genetics and Society, Leuven, Belgium

24. Oslo University Hospital Ullevål and Institute of Clinical Sciences, University of Oslo, Oslo, Norway

25. Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Innovation and Research, Diakonhjemmet Hospital, Oslo, Norway

26. Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm,Sweden

27. Sweden Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden

28. Liverpool Health Partners, Liverpool, UK

Abstract

Abstract Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

Funder

National Institute on Handicapped Research

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvab063/40312096/pvab063.pdf

Reference15 articles.

1. Integrating genomics into healthcare: a global responsibility;Stark;Am J Hum Genet,2019

2. Delivering genomic medicine in the United Kingdom National Health Service: a systematic review and narrative synthesis;Pearce;Genet Med,2019

3. Wide disparity of clinical genetics services and EU rare disease research funding across Europe;Lynch;J Community Genet,2016